Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Metsera, Inc. ( (MTSR) ) just unveiled an update.
On November 4, 2025, Metsera, Inc. announced that its Board of Directors has deemed a revised acquisition proposal from Novo Nordisk as a ‘Superior Company Proposal’ compared to the existing merger agreement with Pfizer. The Novo Nordisk proposal values Metsera at approximately $10 billion, offering $62.20 per share in cash and contingent value rights up to $24.00 per share, surpassing Pfizer’s revised offer of up to $70.00 per share. Metsera has notified Pfizer, triggering a two-day negotiation period to potentially adjust the terms of their merger agreement. The Board continues to recommend the Pfizer merger to shareholders, with no immediate action required.
The most recent analyst rating on (MTSR) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.
Spark’s Take on MTSR Stock
According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.
Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.
To see Spark’s full report on MTSR stock, click here.
More about Metsera, Inc.
Average Trading Volume: 2,271,252
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.39B
Learn more about MTSR stock on TipRanks’ Stock Analysis page.